دورية أكاديمية
Long-term clinical and real-world experience with Crohn’s disease treated with anti-tumor necrosis factor-α antibodies
| العنوان: | Long-term clinical and real-world experience with Crohn’s disease treated with anti-tumor necrosis factor-α antibodies |
|---|---|
| المؤلفون: | Haruka Otake, Satohiro Matsumoto, Hirosato Mashima |
| المصدر: | Intestinal Research, Vol 20, Iss 4, Pp 464-474 (2022) |
| بيانات النشر: | Korean Association for the Study of Intestinal Diseases, 2022. |
| سنة النشر: | 2022 |
| المجموعة: | LCC:Medicine LCC:Diseases of the digestive system. Gastroenterology |
| مصطلحات موضوعية: | crohn disease, infliximab, adalimumab, loss of response, c-reactive protein to albumin ratio, Medicine, Diseases of the digestive system. Gastroenterology, RC799-869 |
| الوصف: | Background/Aims Although anti-tumor necrosis factor (TNF)-α agents are important therapeutic drugs for Crohn’s disease (CD), data regarding their long-term sustained effects are limited. Herein, we evaluated the long-term loss of response (LOR) to anti-TNF-α agents in patients with CD. Methods This retrospective study included patients with CD who started treatment with infliximab or adalimumab as a first-line therapeutic approach. The cumulative event-free, retention, and surgery-free rates after the start of biological therapy were analyzed. Secondary LOR was analyzed in patients who achieved corticosteroid-free clinical remission after the start of biological therapy. Cox proportional hazards models were used to analyze the predictive factors of secondary LOR. Results The cumulative event-free rates at 1, 2, 5, and 10 years were 83.3%, 75.1%, 37.4%, and 23.3%, respectively. The incidence of LOR was 10.6% per patient-year of follow-up. At 12–14 weeks after the start of biological therapy, the proportion of patients with a C-reactive protein to albumin (CRP/ALB) ratio ≥0.18 was significantly higher in patients with LOR (P |
| نوع الوثيقة: | article |
| وصف الملف: | electronic resource |
| اللغة: | English |
| تدمد: | 1598-9100 2288-1956 |
| العلاقة: | http://irjournal.org/upload/pdf/ir-2021-00139.pdfTest; https://doaj.org/toc/1598-9100Test; https://doaj.org/toc/2288-1956Test |
| DOI: | 10.5217/ir.2021.00139 |
| الوصول الحر: | https://doaj.org/article/408c37a7990a46eb8a9ab75915b8817cTest |
| رقم الانضمام: | edsdoj.408c37a7990a46eb8a9ab75915b8817c |
| قاعدة البيانات: | Directory of Open Access Journals |
Full Text Finder | ResultId |
1 |
|---|---|
| Header |
edsdoj Directory of Open Access Journals edsdoj.408c37a7990a46eb8a9ab75915b8817c 991 3 Academic Journal academicJournal 991.065307617188 |
| PLink |
https://search.ebscohost.com/login.aspx?direct=true&site=eds-live&scope=site&db=edsdoj&AN=edsdoj.408c37a7990a46eb8a9ab75915b8817c&custid=s6537998&authtype=sso |
| FullText |
Array
(
[Availability] => 0
)
Array ( [0] => Array ( [Url] => https://doaj.org/article/408c37a7990a46eb8a9ab75915b8817c [Name] => EDS - DOAJ [Category] => fullText [Text] => View record in DOAJ [MouseOverText] => View record in DOAJ ) [1] => Array ( [Url] => https://resolver.ebscohost.com/openurl?custid=s6537998&groupid=main&authtype=ip,guest&sid=EBSCO:edsdoj&genre=article&issn=15989100&ISBN=&volume=20&issue=4&date=20221001&spage=464&pages=464-474&title=Intestinal Research&atitle=Long-term%20clinical%20and%20real-world%20experience%20with%20Crohn%E2%80%99s%20disease%20treated%20with%20anti-tumor%20necrosis%20factor-%CE%B1%20antibodies&id=DOI:10.5217/ir.2021.00139 [Name] => Full Text Finder (s6537998api) [Category] => fullText [Text] => Full Text Finder [Icon] => https://imageserver.ebscohost.com/branding/images/FTF.gif [MouseOverText] => Full Text Finder ) ) |
| Items |
Array
(
[Name] => Title
[Label] => Title
[Group] => Ti
[Data] => Long-term clinical and real-world experience with Crohn’s disease treated with anti-tumor necrosis factor-α antibodies
)
Array ( [Name] => Author [Label] => Authors [Group] => Au [Data] => <searchLink fieldCode="AR" term="%22Haruka+Otake%22">Haruka Otake</searchLink><br /><searchLink fieldCode="AR" term="%22Satohiro+Matsumoto%22">Satohiro Matsumoto</searchLink><br /><searchLink fieldCode="AR" term="%22Hirosato+Mashima%22">Hirosato Mashima</searchLink> ) Array ( [Name] => TitleSource [Label] => Source [Group] => Src [Data] => Intestinal Research, Vol 20, Iss 4, Pp 464-474 (2022) ) Array ( [Name] => Publisher [Label] => Publisher Information [Group] => PubInfo [Data] => Korean Association for the Study of Intestinal Diseases, 2022. ) Array ( [Name] => DatePubCY [Label] => Publication Year [Group] => Date [Data] => 2022 ) Array ( [Name] => Subset [Label] => Collection [Group] => HoldingsInfo [Data] => LCC:Medicine<br />LCC:Diseases of the digestive system. Gastroenterology ) Array ( [Name] => Subject [Label] => Subject Terms [Group] => Su [Data] => <searchLink fieldCode="DE" term="%22crohn+disease%22">crohn disease</searchLink><br /><searchLink fieldCode="DE" term="%22infliximab%22">infliximab</searchLink><br /><searchLink fieldCode="DE" term="%22adalimumab%22">adalimumab</searchLink><br /><searchLink fieldCode="DE" term="%22loss+of+response%22">loss of response</searchLink><br /><searchLink fieldCode="DE" term="%22c-reactive+protein+to+albumin+ratio%22">c-reactive protein to albumin ratio</searchLink><br /><searchLink fieldCode="DE" term="%22Medicine%22">Medicine</searchLink><br /><searchLink fieldCode="DE" term="%22Diseases+of+the+digestive+system%2E+Gastroenterology%22">Diseases of the digestive system. Gastroenterology</searchLink><br /><searchLink fieldCode="DE" term="%22RC799-869%22">RC799-869</searchLink> ) Array ( [Name] => Abstract [Label] => Description [Group] => Ab [Data] => Background/Aims Although anti-tumor necrosis factor (TNF)-α agents are important therapeutic drugs for Crohn’s disease (CD), data regarding their long-term sustained effects are limited. Herein, we evaluated the long-term loss of response (LOR) to anti-TNF-α agents in patients with CD. Methods This retrospective study included patients with CD who started treatment with infliximab or adalimumab as a first-line therapeutic approach. The cumulative event-free, retention, and surgery-free rates after the start of biological therapy were analyzed. Secondary LOR was analyzed in patients who achieved corticosteroid-free clinical remission after the start of biological therapy. Cox proportional hazards models were used to analyze the predictive factors of secondary LOR. Results The cumulative event-free rates at 1, 2, 5, and 10 years were 83.3%, 75.1%, 37.4%, and 23.3%, respectively. The incidence of LOR was 10.6% per patient-year of follow-up. At 12–14 weeks after the start of biological therapy, the proportion of patients with a C-reactive protein to albumin (CRP/ALB) ratio ≥0.18 was significantly higher in patients with LOR (P ) Array ( [Name] => TypeDocument [Label] => Document Type [Group] => TypDoc [Data] => article ) Array ( [Name] => Format [Label] => File Description [Group] => SrcInfo [Data] => electronic resource ) Array ( [Name] => Language [Label] => Language [Group] => Lang [Data] => English ) Array ( [Name] => ISSN [Label] => ISSN [Group] => ISSN [Data] => 1598-9100<br />2288-1956 ) Array ( [Name] => NoteTitleSource [Label] => Relation [Group] => SrcInfo [Data] => http://irjournal.org/upload/pdf/ir-2021-00139.pdf; https://doaj.org/toc/1598-9100; https://doaj.org/toc/2288-1956 ) Array ( [Name] => DOI [Label] => DOI [Group] => ID [Data] => 10.5217/ir.2021.00139 ) Array ( [Name] => URL [Label] => Access URL [Group] => URL [Data] => <link linkTarget="URL" linkTerm="https://doaj.org/article/408c37a7990a46eb8a9ab75915b8817c" linkWindow="_blank">https://doaj.org/article/408c37a7990a46eb8a9ab75915b8817c</link> ) Array ( [Name] => AN [Label] => Accession Number [Group] => ID [Data] => edsdoj.408c37a7990a46eb8a9ab75915b8817c ) |
| RecordInfo |
Array
(
[BibEntity] => Array
(
[Identifiers] => Array
(
[0] => Array
(
[Type] => doi
[Value] => 10.5217/ir.2021.00139
)
)
[Languages] => Array
(
[0] => Array
(
[Text] => English
)
)
[PhysicalDescription] => Array
(
[Pagination] => Array
(
[PageCount] => 11
[StartPage] => 464
)
)
[Subjects] => Array
(
[0] => Array
(
[SubjectFull] => crohn disease
[Type] => general
)
[1] => Array
(
[SubjectFull] => infliximab
[Type] => general
)
[2] => Array
(
[SubjectFull] => adalimumab
[Type] => general
)
[3] => Array
(
[SubjectFull] => loss of response
[Type] => general
)
[4] => Array
(
[SubjectFull] => c-reactive protein to albumin ratio
[Type] => general
)
[5] => Array
(
[SubjectFull] => Medicine
[Type] => general
)
[6] => Array
(
[SubjectFull] => Diseases of the digestive system. Gastroenterology
[Type] => general
)
[7] => Array
(
[SubjectFull] => RC799-869
[Type] => general
)
)
[Titles] => Array
(
[0] => Array
(
[TitleFull] => Long-term clinical and real-world experience with Crohn’s disease treated with anti-tumor necrosis factor-α antibodies
[Type] => main
)
)
)
[BibRelationships] => Array
(
[HasContributorRelationships] => Array
(
[0] => Array
(
[PersonEntity] => Array
(
[Name] => Array
(
[NameFull] => Haruka Otake
)
)
)
[1] => Array
(
[PersonEntity] => Array
(
[Name] => Array
(
[NameFull] => Satohiro Matsumoto
)
)
)
[2] => Array
(
[PersonEntity] => Array
(
[Name] => Array
(
[NameFull] => Hirosato Mashima
)
)
)
)
[IsPartOfRelationships] => Array
(
[0] => Array
(
[BibEntity] => Array
(
[Dates] => Array
(
[0] => Array
(
[D] => 01
[M] => 10
[Type] => published
[Y] => 2022
)
)
[Identifiers] => Array
(
[0] => Array
(
[Type] => issn-print
[Value] => 15989100
)
[1] => Array
(
[Type] => issn-print
[Value] => 22881956
)
)
[Numbering] => Array
(
[0] => Array
(
[Type] => volume
[Value] => 20
)
[1] => Array
(
[Type] => issue
[Value] => 4
)
)
[Titles] => Array
(
[0] => Array
(
[TitleFull] => Intestinal Research
[Type] => main
)
)
)
)
)
)
)
|
| IllustrationInfo |